All lobbying filings

TIBER CREEK GROUP

Lobbying for MERCK & CO., INC · Prescription medicines, vaccines, and biologic therapies

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 19, 2026

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act
HR 8857
Next GEN Act of 2026

Lobbying activity 3

Medicare/Medicaid

Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026.

Trade (domestic/foreign)

Issues related to intellectual property protections.

Health Issues

Issues related to immunization policy.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.